Vol. 12, Issue 6 (2023)

Author(s):
Mudhalvan S, Swathi M, Lena E Augustin, Thanga Pushpam R and Sindhu S

Abstract:
This survey's objective is to identify and describe new plant biotechnology products that have come onto the market since 2010, with a focus on those that are related to the development of New Breeding Techniques (NBTs), such as gene editing using the CRISPR-Cas system. We compile information on transgenic (gene transfer or gene silencing) and gene edited features that have received approval or are commercialised in at least one nation, or that are not subject to regulation in India. We also compile information on related patents from around the world. Also looked at are field trials conducted across the continent to offer insight on prospective innovations for India. Agronomic advancements, industrial use, and medical use specifically, the synthesis of recombinant medicinal molecules are all classed within the application categories in which the data have been assembled. According to the statistics, gene editing does not appear to be a replacement for 'classical' transgenesis, the usage of which is increasing, but rather a useful addition to it. This is a tendency that has also been seen in the patenting environment. However, it is clear that gene editing is being used more frequently. In comparison to transgenesis, gene editing has resulted in a rise in some crop species and a decrease in others among crops that have been approved, unregulated, or commercialised. Breeding traits show a similar divergent tendency. New private businesses have benefited from gene editing as well. The patenting landscape is overwhelmingly dominated by China, particularly by its governmental sector, as opposed to the approved/marketed landscape, which is dominated by the USA. The statistics suggest that regulatory frameworks will encourage or stifle innovation.